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“A STUDY ON MEAN TSH LEVELS AND VARIOUS PERINATAL FACTORS 
AFFECTING TSH LEVELS IN THE CORD BLOOD OF NEWBORN” 
                                                             ABSTRACT  
BACKGROUND  
 Congenital  hypothyroidism  is  the most common preventable  cause  of  mental  
retardation .Neonatal  screening  methods  measure  either  cord blood  TSH  or  heel  
prick  sample .Cord  blood  TSH  has  high  sensitivity  but  with  a  high false  positive  
values  due to confounding factors and requires evaluation. 
OBJECTIVE 
To study the mean TSH levels and various perinatal factors affecting TSH levels 
in cord blood of newborn. 
OBSSRVATION AND ANALYSIS 
It is a descriptive cross sectional study  and 110 cord blood samples are  analyzed 
and TSH levels are measured. The nine variables included in the study are parity of 
mother, gestational diabetes mellitus, mode of delivery, birth weight, gestational age, sex, 
weight appropriate for gestation, requirement of resuscitation and apgar score. The p 
value, ROC curve, test of significance and criterion cut off levels are made for each of the 
variables. Among 9 variables, the emergency LSCS (p <0.001), low apgar 
score(p<0.0259) and requirement of resuscitation(p<0.0292) have  significant p values 
and found to be statistically significant. In our study 20 among 110 cord samples  are 
found to have CBTSH levels above the cut off value of 13.1 and repeat venous sampling 
done on 5th
 
 day of life . All venous sample TSH levels found to be lower than cut off 
TSH levels and reveals that the high cord blood TSH levels are due to perinatal stress 
factors such as emergency LSCS, resuscitation and low  apgar score which has significant 
positive correlation as evidenced with P values in our study. 
RESULTS 
  In our study emergency lscs, low apgar score and requirement of resuscitation 
affects cord blood TSH levels.  
 KEYWORDS 
          Thyroid stimulating hormone (TSH), Cord blood TSH, perinatal  factors, 
emergency lscs, resuscitation , mean TSH level. 
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INTRODUCTION 
Thyroid is a small endocrine gland, which is brownish red in colour, 
located anteriorly in the lower neck extending from the level of fifth cervical 
vertebra to the first thoracic vertebra.  It utilizes iodine to synthesise thyroid 
hormones.  These thyroid hormones are essential for normal growth, 
development and various metabolic regulations in the body.  Therefore, the 
thyroid hormone deficiency results in short stature, cretinism, intellectual 
disability, mutism etc.  
Congenital hypothyroidism is the most common preventable cause of 
mental retardation.  The worldwide incidence is 1:3000 – 1:4000[1].  The 
estimated incidence in India is 1:2500 – 1:2800 live birth.  Clinical diagnosis is 
difficult at birth and the time of initiation of therapy is critical in the 
determinant of outcome.  
Neonatal screening methods measure either cord blood TSH level or 
heel prick sample at 3 to 5 days of life.  Therefore Cord blood TSH is an 
accepted screening tool for congenital hypothyroidism.  Cord blood TSH has 
high sensitivity but with a high false positive values and a wide range of values 
causes high recall rates requiring evaluation for confounding factors 
contributing to increase in TSH values.  Moreover various maternal and 
perinatal factors are known to affect TSH levels.  
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AIM OF THE STUDY 
To evaluate the mean TSH levels and various perinatal factors affecting 
TSH levels in cord blood of newborn.  
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REVIEW OF LITERATURE 
1.   Herbstman et al,[3] study on perinatal factors affecting cord blood TSH 
levels among 300 newborns reveals that several perinatal factors such as 
maternal age, gestational diabetes, pregnancy induced hypertension, 
gestational age,alcohol use during pregnancy can affect thyroid hormone 
status in the cord blood.  
2.   Eun young Kim et al(korea). [6], study on 130 neonates reavealed that 
cord blood TSH levels is affected by perinatal stress events.   
3.   Fuse et al., (japan)[5],study on 124 healthy newborns with different 
types of delivery including normal vaginal delivery,cesarean and 
vacuum extractor revealed that there is no statistically significant 
difference in cord blood TSH among study group.  
4.   Franklin et al. [2], in his study on 229 newborns revealed that perinatal 
factors such as birth weight and mode of delivery significantly affect 
cord blood TSH.  
5.   Gupta, srivastava, bhatnagar et. al. ,(india) study on perinatal factors 
affecting cordblood TSH levels among 952 Indian live newborn showed 
that fetal distress, mode of delivery and requirement of resuscitation 
significantly affect cord blood TSH levels.  
6.  Miyamato N et. al. ,. [4] study on influence of mode of delivery on 
pituitary- thyroid axis among 922 newborns showed that the cord bood 
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TSH level reflects delivery stress and an elevated level does not 
influence the TSH screening test for congenital hypothyroidism in which 
blood is obtained at five days of life.  
7.  Armenian et al. (Isfahan,iran),in a study of perinatal factors 
influencing cord blood TSH in Isfahan iran in 2012 involving 440 
newborns revealed that mode of delivery significantly affect.  cord blood 
TSH.  
8.  Chan LY,leung TN et. al[8], study on 24,892 babies showed that cord 
blood TSH levels reflects fetal response to perinatal factors.  
9.  Sunil raj et al.,(india) study on cord blood TSH level variations in 
newborn- Experience from rural southern india revealed that the mode 
of delivery significantly affects cord blood TSH.   
10.  Turan S et. al. ,[7] study of effect of mode of delivery on neonatal 
thyroid function among 638 newborns reveals that there is significant 
correlation between mode of delivery and cord blood TSH levels.  
THYROID GLAND EMBYOLOGY:  
  The thyroid gland develops from the 3rd branchial arch as an endodermal 
thickening and some cells originate from the 4th branchial arch. The main 
anlage of the thyroid gland develops at foramen caecum.  The anlage descends 
from the base of tongue as the thyroid diverticulum and it leaves the 
thyroglossal duct, which in turn connected to the foramen caecum and it 
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crosses anterior to the hyoid bone and thyroid cartilage.  The thyroid gland 
hence settles as a bilobed organ inferior to the thyroid cartilage, one lobe on 
each side anterolateral to the trachea.  The two lobes of the gland is connected 
by an isthmus which unites the lobes anterior to the second and third tracheal 
rings.   
The appearance of thyroid follicles is the next stage of development 
which occurs between ninth and tenth weeks of the gestation.  The thyroid 
follicle composed of a layer of cells arranged around a big central cavity which 
is filled with a colloid like material, consists largely of the protein called as 
thyroglobulin.  There are three types of cells become apparent.  A cells also 
known as perifollicular endothelial cells, are responsible for the blood supply to 
the follicles.  The predominant cells having an affinity for iodine and to 
synthesise iodothyronine hormones T3 and T4 are called as B cells or follicular 
cells. Calcitonin producing cells are called as C cells or parafollicular cells 
which develops from endoderm while A and B cells develops from ectoderm. 
TSH plays an important and major role in thyroid gland development.  
  Thyroid stimulating hormone(TSH) is a glycoprotein hormone.  
Thyrotropin releasing hormone is secreted by the hypothalamus.  Once 
released, it reaches the anterior pituitary through the hypophyseal pituitary 
portal circulation.  TSH is stored in the anterior pituitary and is consequently to 
be released when stimulated.  TSH has a trophic affect on the gland stimulating 
its growth.  The other affects of TSH on the thyroid gland include: increase in 
release of stored thyroid hormones, increase in thyroid hormone synthesis.  As 
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mentioned, these hormones are responsible for regulating the rates of metabolic 
processes throughout the body.  
Upon completion of development of the thyroid, the gland is surrounded 
by a thin fibrous capsule, which sends septa deeply into the gland.  External to 
the capsule is a loose sheath formed by the visceral layer of the prevertebral 
deep cervical fascia.  
Dense connective tissue connects the capsule of the thyroid gland to the 
cartilage and the superior tracheal rings.  Two pairs Para follicular cells (C 
cells) from the neural crest reach the thyroid via ultimo branchi.  The four 
transcription factors – TTF -1, PAX8, FOXe1, HheX are important in thyroid 
morphogenesis and differentiation.  
Foetal thyroid gland [1] recognized by 7th week of gestation, colloid 
formation at 10wk, iodine trapping by 8-10 week, thyroglobulin synthesis from 
4th week, T3 – synthesis and secretion by 12 weeks, TRH by 6-8 weeks and 
TSH by 12 weeks of life.  
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THYROID HISTOLOGY: 
There are three primary features at microscopic level of thyroid gland 
first discovered by geoffery websterson.  
FOLLICLES: 
Thyroid gland is composed of numerous follicles which is spherical in 
shape that absorbs iodine in the form of iodide ions from the blood to produce 
thyroid hormones.  It is composed of cuboidal epithelium in resting stage and 
becomes columnar epithelium during active state.  Thyroid gland comprises 
25% of body total iodine content.  Follicular lumen inside thyroid follicles, 
contains colloid which serves as a reservoir of materials for thyroid hormone 
production and, also acts as a reservoir for the hormones themselves.  Colloid 
is rich in thyroglobulin which is a glycoprotein dimer molecule.  
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Follicular cells 
The follicles are surrounded by a single layer of follicular cells, which 
secrete T3 and T4.  When the gland is in resting stage the epithelium is low 
columnar to cuboidal cells.  It becomes columnar when the gland is in active 
stage.  
Parafollicular cells 
Among follicular cells, there are cells which are scattered in spaces 
between the spherical follicles are called parafollicular (also called “C cells”), 
which secrete calcitonin.  
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THYROID HORMONE BIOSYNTHESIS : 
     Thyroid hormones ( T3, T4 ) are produced by follicular cells of the 
thyroid gland and regulated by TSH (thyroid stimulating hormone).  the first 
step in thyroid hormone biosynthesis[3,4] is iodide trapping with the help of Na / 
I symporter pumps idide (I -) [ which concentrates I- by active transport].  
Iodide is oxidized with the help of thyroid peroxidase.   
   Iodination of tyrosine[3] (organification ) residue in thyroglobulin is a 
reaction that involves thyroperoxidase to form MIT /DIT 
Coupling of iodotyrosins (MIT /DIT ) residues to form T3 & T4, rT3 
respectively and hydrolysis of thyroglobulin molecule by activation of 
proteases and peptidases results in release of T3, T4 hormones[10].  
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  Thyroid produces approximately 100mcg of T4 and 20mcg of T3 daily.  
Deiodination of T4 in the liver, kidney and peripheral tissues by type-I 5’- 
deiodinase contributes 80% of circulating T3 hormone and in brain it is carried 
out with the enzyme type-II 5’-deiodinase[10,14].   
The T3 hormone level in blood is 1/50th of that of T4, but T3 is 3-4times 
more potent than T4[1].  Thyroxine binding globulin (TBG) binds 70% of 
circulating T4 hormone.  And 50% of T3 is bound to TBG.  Free T4 is only 0. 
03% and 0. 30% of T3 is unbound.  Less important thyroid carriers are 
thyroxine binding pre albumin called transthyretin and albumin.   
THYROID HORMONE REGULATION: 
There is a negative feedback mechanism which is operating in thyroid 
hormone regulation.  Thyrotropin releasing hormone(TRH) which is secreted 
from hypothalamus stimulates anterior pituitary somatotropes to release TSH 
hormone.  This released thyroid stimulating hormone acts on TSH receptors 
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present in the thyroid gland to produce T4 and T3 hormones.  The released T3 
and T4 hormone inturn inhibits the TSH release.  
 
Thyroid hormone action : 
    Thyroid hormone exerts its function through thyroid receptors which are 
intracellular similar to steroid hormone receptor superfamily.  
Physiological effects 
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METABOLIC EFFECTS: 
    It increases the basal metabolic rates, therefore increases body heat 
production.  It increases lipolysis leading to an increase in concentration of free 
fatty acids in plasma.  As far as carbohydrate metabolism is concerned thyroid 
hormone increases, gluconeogenesis[7], glucogenolysis and enhance the insulin 
dependent entry of glucose into the cells. Thyroid hormone is essential for 
normal growth and development in children [8].   
Cardiovascular system: - It increases heart rate cardiac 
contractility,cardiac output and causes vasodilatation in peripheral system.  
REPRODUCTIVE SYSTEM:  
Normal physiology and reproductive behavior[7,8] is dependent on 
normal levels of thyroid hormone.  
HYPOTHYROIDISM: 
Defined as deficient thyroid hormones (T3 and T4) resulting from either 
deficient production or defect in thyroid hormone receptors. It can be 
congenital or acquired.  
TYPES: 
1.  CONGENITAL HYPOTHYROIDISM 
2.  PERMANENT HYPOTHYROIDISM 
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CONGENITAL HYPOTHROIDISM: 
1.  PERMANENT HYPOTHYROIDISM 
2.  TRANSIENT HYPOTHYROIDISM 
PERMANENT HYPOTHRIDISM 
a.  Thyroid dysgenesis (aplasia,hypoplasia or ectopia) 
b.  Thyroid hormone biosynthetic defects  
c.  hypothalamic-pituitary hypothyroidism 
d.  Iodine deficiency (endemic cretinism) 
2.  TRANSIENT HYPOTHYROIDISM: 
a.  TSH binding inhibitory immunoglobulins 
b. Goitrogen exposure 
c.  sick euthyroid syndrome 
d.  Transient hypothyroxinemia of prematurity 
CONGENITAL HYPOTHYROIDISM: 
The prevalence of congenital hypothyroidism worldwide is 1:4000 
based on neonatal nationwide screening program[32].  Highest prevalence in 
Hispanics and lowest in black Americans.  Girls are affected twice than boys.  
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ETIOLOGY: 
THYROID DYSGENESIS: 
Most common cause for congenital hypothyroidism is thyroid 
dysgenesis[17,18]. It can be aplasia,hypoplasia or ectopic gland.  It accounts for 
80% cases of congenital hypothyroidism. Thyroid dysgenesis occurs mostly 
sporadic but familial cases can be reported.  
Mutations in the following three transcription factors, TTF-1,FOXE1 
and PAX8 are associated with thyroid dysgenesis. Mutations in NKX2. 1[19] 
resulting in both congenital hypothyroidism and neurological problems. 
Among thyroid dysgenesis, ectopic gland is the most common form. Surgical 
removal of the ectopic gland results in hypothyroidism.  
DYSHORMONOGENESIS: 
It is the second most common cause for congenital hypothyroidism.  It is 
inherited in autosomal recessive manner.  
Other etiologies include defect of iodide transport, thyroid peroxidase 
defects, thyroglobulin synthesis defects, defects in deiodination, defects in 
thyroid hormone transport, thyroid receptor blocking antibody, radioiodine 
administration, thyrotropin deficiency and thyroid hormone unresponsiveness.  
TRANSIENT HYPOTHYROIDISM : 
The transplacental transfer of TSH binding inhibitory 
immunoglobulins(TBII) from mother with autoimmune thyroid disease to fetus 
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results in transient hypothyroidism.  The incidence of which is 1:50,000 live 
births. The inhibitory effect of this TSH binding inhibitory immunoglobulin 
effect weans in 3 to 6 months, after which the infant become euthyroid.  
Iodine exposure (POVIDONE IODINE application ) or iodine intake in 
preganant women either by dietary goitrogens or iodine containing medications 
results in transient hypothyroidism of newborn especially in sick preterm 
infants(WOLF- CHAIKOFF EFFECT) 
TRANSIENT HYPOTHYROXINEMIA OF PREMATURITY: 
In comparison to term infants, upto 85% of preterm babies have low 
serum concerntration of thyroid hormones. This is due to underdevelopment of 
hypothalamic[13] pituitary axis.  This condition is associated with decreased 
survival and impaired neurodevelopmental outcomes.   
SICK EUTHYROID SYNDROME: 
This condition is associated with inappropriately low TSH levels in the 
context of low T3 due to suppressed pituitary response to the TRH hormone.  
CLINICAL MANIFESTATIONS: 
Newborn with congenital hypothyroidism are usually asymptomatic[17] 
at birth, even if there is complete agenesis. This is due to transplacental transfer 
of T4 from mother to fetus and it contributes to almost 33% of fetal thyroid 
hormonal levels. Therefore clinical diagnosis for congenital hypothyroidism at 
birth is difficult and this mandates the neonatal screening.  
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CLINICAL FEATURES: 
Birth weight and length is normal. The head size is slightly increased 
due to myxedema of brain. The earliest sign may be the prolongation of 
jaundice.  Excessive somnolence,lack of intertest and feeding difficulties are 
present during first few months of life. Noisy breathing,nasal obstruction, 
apneic episodes and respiratory difficulties occurs due to large tongue.  
Affected infants have poor appetites and constipation[17,18] which may not 
respond to treatment. The abdomen is large and umbilical hernia may be 
present. The tempertature is often subnormal (<35c) and the extremities may be 
mottled. Heart murmurs,cardiomegaly,slow volume pulse are the common 
cardiovascular findings.  Macrocytic anaemia which is refractory to hematinics 
may be present 
CONGENITAL ANOMALIES: 
The incidence of congenital anomalies in association with congenital 
hypothyroidism is 10%. Among which cardiac anomalies are most common. 
The less common anomalies includes CNS anomalies,visual and hearing 
defects.  
UNTREATED HYPOTHYROIDISM: 
The child’s growth will be stunted and the extremities are short.  The 
anterior and posterior fontanels are wide open.  The eyes are widely spaced and 
the nose is broad and depressed.  The palpebral fissures appear narrow as a 
result of swollen myxedematous eyelids[17]. The mouth is wide open with broad 
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protruding tongue.  There will be delayed dentition.  The neck is short and 
there will be deposition of fat above clavicles.  The skin is dry, scaly and cold 
with very little perspiration. The hand appears broad with short fingers.  The 
hair is coarse,scanty,brittle in nature.  Myxedema is present particularly in the 
skin of eyelids,dorsal aspect of hands and external genitals.  
Developmental delay is almost always universal in untreated and 
undetected cases. There is both physical and mental development delay, which 
increases with age. Sexual maturation may be delayed with infantile appearing 
genitals. The muscles are usually hypotonic, but in some cases there is 
generalized pseudohypertrophy of muscles (KOCHER - DEBRE-
SEMALAIGNE SYNDROME)[17]. The affected children may have athletic 
appearance due to calf muscle pseudohypertrophy.  
DIAGNOSIS: 
NEWBORN SCREENING: 
Universal newborn screening should be done on 3 to 4 days of life. It 
can be done either on venous sample or heelprick method along with other 
metabolic screening or using cordblood sample. The three approaches are 
1. Primary TSH, back up T4 
2. Primary T4, back up TSH 
3. Concomitant T4 and TSH 
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PRIMARY TSH, BACK UP T4:  
In this approach, TSH is measured first and if TSH is >20mu/L, T4 is 
measured. This approach is commonly used and is cost effective. The 
limitation of this approach is that, it will likely to miss central hypothyroidism, 
thyroid binding globulin(TBG) deficiency and hypothyroxinemia with delayed 
elevation of TSH. [14’15] 
PRIMARY T4, BACK UP TSH: 
T4 is measured first and if it the level is low, TSH is measured. 
Subclinical hypothyroidism will be missed in this approach because in this 
condition T4 is normal initially with elevated TSH.  
CONCOMITANT T4 AND TSH: 
Most effective and sensitive approach but with limitation of higher cost.  
The neonatal screening programs for universal standardization use either 
percentile based cutoffs (eg. T4 below 10th centile or TSH levels above 90th 
centile or absolute cut-offs such as T4< 6. 5ug/dl and TSH >20mu/L.  It is 
estimated that TSH is >50mu/l in 90% and T4 is >6. 5ug/dl in more than 75% 
of proven congenital hypothyroidism. Abnormal values on screening should 
always be confirmed with venous sample. Any infant with the following signs 
and symptoms of hypothyroidism such as postmaturity,macrosomia or wide 
open posterior fontanel or prolonged jaundice, constipation, hoarse cry, 
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umbilical hernia, macroglossia,poor feeding,edematous dry skin should always 
be screened for hypothyroidism.  
Investigations to determine the etiology should be done once the 
diagnosis is made.  
DIAGNOSTIC STUDIES FOR EVALUATION OF CONGENITAL 
HYPOTHYROIDISM: 
1. IMAGING STUDIES: to determine the location and size of thyroid gland.  
A.  scintigraphy(99mTc or 123 I) 
B.  sonography 
2.  FUNCTION STUDIES: 
A.  123I uptake 
B.  serum thyroglobulin 
3. SUSPECTED INBORN ERROR OF T4 SYNTHESIS 
A. 123I uptake and perchlorate discharge 
4. SUSPECTED AUTOIMMUNE THYROID DISEASE 
A. maternal and neonatal serum TBII( thyroid binding immunoglobulin) 
measurement 
5. SUSPECTED IODINE EXPOSURE OR DEFICIENCY 
A. urinary iodine measurement 
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6. Radiograph of knee for skeletal maturation.  
RADIOLOGICAL FEATURES IN HYPOTHYROIDISM: 
Retardation of ossesous development[17] can be found in almost 60% 
cases of congenital hypothyroidism. This indicates the lack of thyroid 
hormones during intrauterine life. The epiphysis of distal femur and proximal 
tibia often absent which is evidenced with radiography of knee. In severe 
hypothyroidism and untreated cases,there is discrepancy between chronological 
age and bone age will be there. The other radiological features include 
epiphyseal dysgenesis and beaking of T12 vertebra and L1 or L2 vertebra.  
Large fontanels,wide open sutures and wormian bones are often present in xray 
skull.  
FREE T4 LEVELS: 
Total T4 levels are sufficient to make diagnosis and monitor treatment in 
most clinical conditions. But free T4 levels are considered to be the robust 
marker for bioavaialable T4.  It is indicated in the following conditions: 
1. PRETERM OR SICK NEWBORNS: 
In such babies total T4 levels may be low due to abnormal protein 
binding or low levels of thyroxine binding globulin. Therefore instead of total 
T4 values in these babies, free T4 values provide a reliable estimate of thyroid 
function.  
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2. A CASE OF LOW T4 WITH NORMAL TSH: 
If free T4 levels is normal in this situation,congenital thyroid binding 
globulin(TBG) deficiency should be considered. Along with low T4, normal 
TSH if the free T4 levels is low,central hypothyroidism be suspected.  
3. FOR MONITORING THE ADEQUACY OF TREATMENT 
TREATMENT: 
Levothyroxine given as oral medication is the drug of choice for 
congenital hypothyroidism. Moreover 80 % of circulating T3 hormone formed 
as a result of monodeiodination of T4 hormones both in peripheral circulation 
and brain. Therefore both T3 and T4 hormones returns to normal levels with 
levothyroxine treatment.  
DOSAGE: 
The recommended starting dose of levothyroxine in newborn is 10-
15ug/kg. For severe hypothyroidism as confirmed by TSH,T3,T4 levels,needs 
higher dosage range.   
MONITORING OF THERAPY:  
The therapeutic goal is to maintain the T4 in the upper half of normal 
range(10 to 16ug/dl) or free T4 in the range of 1. 4 to 2. 3 ng/dl and TSH 
suppressed in normal range.  
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Monitor T4 and TSH levels according to the following schedule: 
1. 0-6 months: every 6 weeks 
2. 6months to 3 years :every 3 months 
3. Beyond 3 years: every 6 months 
4. 6 to 8 weeks after any dosage change 
5.  Frequent monitoring of growth and development of the child.  
Overtreatment may result in premature closure of sutures( 
craniosynostosis), pseudotumour cerebri,premature epiphyseal closure and 
temperament problems.   
ACQUIRED HYPOTHYROIDISM:  
The prevalence of acquired hypothyroidism among school aged children 
is 0. 3%. The most common cause is chronic lymphocytic thyroiditis and the 
male to female ratio is 1:2 
ETIOLOGY: 
AUTOIMMUNE DISEASE: 
Chronic lymphocytic thyroiditis(hashimotos thyroiditis) is the most 
common cause of acquired hypothyroidism. Polyglandular autoimmune 
syndrome can be associated with associated autoimmune thyroid disease. 
Autoimmune thyroid disease can be a part of chromosomal anomalies like 
downs syndrome,klinefelter syndrome,turner syndrome and diabetes. There is 
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increased risk of hypothyroidism with Addison disease,sjogren 
syndrome,perinicious anemia.  
ANTITHYROID DRUGS: 
Propylthiouracil,methimazole,iodides,lithium,amiodarone are the 
medications that causes hypothyroidism. Amiodarone which is used in cardiac 
arrhythmias consists of 37% iodine by weight. It inhibits thyroid function 
directly as well as by inhibition of 5’ deiodinase. It causes hypothyroidism in 
20% of treated patients. Therefore serial measurements of T3,T4and TSH is 
needed in patients on chronic amiodarone therapy.   
IATROGENIC CAUSES: 
Irradiation of thyroid gland area which occurs accidentally during 
treatment of head and neck malignancies, Hodgkin disease causes 
hypothyroidism. Radioiodine therapy itself causes hypothyroidism. Total or 
subtotal thyroidectomy can cause hypothyroidism.  
RARE CAUSES: 
Cystinosis and langerhans cell histiocytosis and liver hemangiomas.  
CLINICAL FEATURES: 
Growth deceleration is the first and most important clinical feature of 
acquired hypothyroidism,which may be unrecognized. A nontender, firm and 
rubbery goiter which may be the presenting feature. Cold intolerance, 
constipation, increased somnolence and myxedematous changes in skin 
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develops over time. The duration of hypothyroidism.  may correlates with 
osseous maturational delay. Galactorrhea and pseudoprecocious puberty may 
be present in younger children. The increased TRH stimulates prolaction 
release which results in galactorrhea. The precocious puberty is due to high 
TRH levels which binds to follicular stimulating hormone receptor and its 
subsequent stimulation.  
The hyperplastic enlargement of pituitary gland due to thyrotroph 
hyperplasia results in visual problems and headache in some children.  The 
other features include weight gain, bradycardia and menstrual irregularities.  
Macrocytic anemia, hyponatremia and,hypercholesterolemia are the abnormal 
laboratory findings. Adequate replacement therapy with levothyroxine will 
reverse all the manifestations of hypothyroidism but there is incomplete catch 
up growth in long standing hypothyroidism.  
MANAGEMENT: 
Diagnosis and treatment is similar to that of congenital hypothyroidism.  
Measurement of antithyroglobulin and antiperoxidase antibodies is necessary 
for making diagnosis of autoimmune disease. Thyroid imaging will shows 
scattered hypoechogenicity.  
HASHIMOTO THYROIDITIS: 
It is otherwise called as lymphocytic thyroiditis or autoimmune 
thyroiditis and it is the most common cause for acquired hypothyroidism in 
children and adolescents with or without goiter. The typical histological feature 
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of hashimoto thyroiditis is lymphocytic infiltration of thyroid gland. There is 
infiltration of lymphocytes and plasma cells in the early stages followed by 
atrophy of follicles and fibrosis, the degree of which varies from mild to 
moderate. Both CD4+(Helper) and CD8+(cytotoxic) cells represents the 
infiltrating lymphoid populations.  
AUTOANTIBODIES IN HASHIMOTO THYROIDITIS: 
Thyroid antiperoxidase antibodies(antimicriosomal antibodies) and 
antithyroglobulin[1,32] antibodies constitutes the major antibodies which is 
detectable in approximately 90% of affected children. Thyrotropin receptor 
blocking antibodies is associated with risk of atrophic thyroiditis and for 
subsequent hypothyroidism. Antibodies to pendrin is present in about 80% of 
patients.  
CLINICAL FEATURES: 
It is twice common in girls than boys. (M:F-2:1). The peak age of 
incidence is adolescence. Goiter and growth retardation are the most important 
clinical features. The thyroid gland is diffusely enlarged, nontender and firm in 
consistency in most patients. It can be lobular and nodular in few patients. In 
the initial course of disease, most of the affected children are asymptomatic and 
euthyroid clinically. Some children can presents with hypothyroidism clinically 
and some with subclinical hypothyroidism. A very few children can presents 
with features such as irritability,increased sweating and nervousness suggestive 
of hyperthyroidism. The disorder can coexists with graves disease. The clinical 
  26
course is highly variable. Some children who remains euthyroid can develop 
overt hypothyroidism as the disease progress.  
This disease is associated with other autoimmune diseases like APS-
1(autoimmune polyglandular syndrome charachterized by autoimmune 
polyendocrinopathy,candidiasis and ectodermal dysplasia) and in 70% patients 
of APS-2. The other associations of hashimotos are pernicious anemia,vitiligo 
and type 1 diabetes mellitus. Thyroid antiperoxidase antibodies(TPOAbs) are 
demonstrable in 28% of downs syndrome and 41% of turner syndrome affected 
children.  
LABORATORY FINDINGS: 
1. THYROID FUNCTION TESTS: 
TSH and freeT4 levels are usually normal, although TSH may be 
elevated slightly or moderately in some patients known as subclinical 
hypothyroidism.  
2. SEROLOGY: 
Thyroid antiperoxidase antibodies (TPOAbs) is detected in most patients 
and antithyrogloblin antibodies in 50% of cases. If both antibodies tests are 
combined, it detects more than 95% of patients with autoimmune thyroiditis.  
3. THYROID IMAGING: 
Thyroid scan reveals irregular and patchy distribution of radioisotope in 
> 60% patients. Administration of perchlorate results in >10% iodide discharge 
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from thyroid gland. Thyroid ultrasound reveals scattered hypoechogenecity in 
most of the affected patients.  
4. THYROID BIOPSY: 
Thyroid biopsy establishes the definitive diagnosis of lymphocytic 
thyroiditis,but rarely indicated in most clinical situations. The features are 
infiltration of lymphocytes and plasma cells and atrophy of follicles. Lymphoid 
follicular formation with germinal centres and varying degrees of atrophy and 
fibrosis.  
TREATMENT: 
Replacement therapy with levothyroxine if there is evidence of 
hypothyroidism at doses based on weight and age.  The goiter gradually 
decreases in size and may persists for years. AntiboIy titres fluctuates over the 
course of disease with treatment and it can persists for years. Periodic 
evaluation of thyroid function tests is necessary as the disease is self limited in 
some instances. Thyroid nodules that persists despite suppressive TSH therapy 
should undergo FNAC to rule out thyroid carcinoma or lymphoma.  
CONGENITAL GOITER: 
Enlargement of thyroid gland is called as goiter or thyromegaly. 
Congenital goiter is due to either a fetal thyoxine(T4) synthetic defect or from 
administration of antithyroid drugs or iodides during for the treatment of 
maternal thyrotoxicosis during pregnancy. Transplacental transfer of 
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goitrogenic drugs[24] interfere with thyroid horm one synthesis and causes both 
goiter and hypothyroidisim in fetus. Antithyroid drugs at higher drugs used in 
treatment of maternal thyrotoxicosis can cause concomitant hypothyroidism in 
mother and reduces the transplacental transfer of thyroid hormones to the fetus. 
Therefore if the mother takes antithyroid medications during third 
trimester,babies should undergo thyroid studies at birth.  
Even if the infant appears euthyroid clinically,there may be low levels of 
T4 and elevated TSH levels and retarded osseous development. Affected 
children with clinical hypothyroidism should be treated with levothyroxine[27] 
to prevent growth retardation and to hasten the disappearance of goiter.  
Thyroid hormones may be discontinued after the antithyroid drug has been 
excreted by the neonate,usually after 1-2 week since this condition is self 
limiting. In addition to antithyroid medications, iodide containing proprietary 
cough preparations and antiarrythmic drug amiodarone can cause congenital 
goiter and hypothyroidism.  
Congenital goiter[28] occasionally be sufficient to cause respiratory 
distress which interefers with nursing and even causes death. There is extreme 
hyperextension of head due to goiter. If there is severe respiratory obstruction 
in the postnatal period, partial thyroidectomy should be done rather than 
tracheostomy. If a massive fetal goiter is detected antenatally either withdrawl 
of antithyroid medications or amniotic thyroid replacement therapy can be 
considered.  
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In congenital hyperthyroidism[29],goiter is almost always present and the 
newborn presents with features of hyperthyroidism. The mother mostly have 
graves disease and the transplacental passage of thyroid stimulating 
immunoglobulin causes goiter in newborn. If there is no identifiable cause, 
defect in thyroid hormone synthesis should be suspected.  
ENDEMIC GOITER AND CRETINISM: 
The association between the prevalence of endemic goiter and cretinism 
with iodine deficiency is well established. There is increased synthesis of 
thyroid hormone in iodine deficiency as a compensatory mechanism. Iodine 
released from tissues is reutilized to synthesize T4 and T3 hormones. This 
increased activity is due to the compensatory hypertrophy and hyperplasia of 
thyroid gland evidenced as goiter. World health organization estimates that 
nearly 2 billion people currently have insufficient iodine intake that includes 
one third of world’s school age children.  
The most serious consequence of iodine deficiency is endemic 
cretinism[32].  It includes two types namely, neurologic type and myxedematous 
type. The neurologic type includes the following features like mental 
retardation,gait disturbances,deaf mutism,pyramidal signs such as 
clonus,babinski sign and hyperreflexia. Goitre will be present but affected 
individuals are euthyroid clinically.  They have normal pubertal development 
and the adult stature within normal limits and have little or no impaired thyroid 
function.  
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The charachteristic feature of myxedematous[36] type is mental 
retardation,deaf mutism and neurological signs.  They also have growth 
retardation, sexual developmental delay, myxedema and absence of goiter.  
Thyroid function tests reveals markedly elevated TSH levels and low T4 levels.   
TREATMENT: 
Iodinated poppy seed oil given as single intramuscular injection to 
women prevents iodine deficiency during future pregnancies for about 5 years.  
Myxedematous[36] children younger than 4years of age given this form of 
treatment will results in euthyroid state in 5 months.  Older children rather they 
require treatment withT4. Universal iodization of salt enacted by world health 
organization reduces the endemic iodine deficiency[38,39,40] about 50%.  
HYPERTHYROIDISM: 
ETIOLOGY: 
A. CIRCULATING THYROID STIMULATORS: 
Graves disease 
Neonatal graves disease 
B. THYROIDAL AUTONOMY: 
Multinodular toxic goiter 
Solitary adenoma 
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Iodine induced hyperthyroidism (jod-basedow phenomenon) 
C. THYROIDITIS:(DESTRUCTION OF THYROID FOLLICLES) 
D. EXOGENOUS THYROID HORMONE: 
E. EXOGENOUS THYROID TISSUE 
GRAVES DISEASE: 
The incidence of graves disease among children is approximately 
1:5000. The peak age of incidence is 11-15yrs and is 5 times more common 
among females than males. (M:F-5:1).  
PATHOGENESIS: 
The failure of suppressor T cells allows the expression of T helper cells 
sensitized to the TSH antigen which interacts with the B cells[32]. These 
sensitized B cells differentiate into plasma cells and produces thyrotropin 
receptor stimulating antibody (TRSAb). This antibody binds to TSH receptor 
and stimulates cyclic adenosine monophosphate(cAMP) pathway similar to 
thyroid stimulating hormone. Apart from TRSAb, thyroid receptor blocking 
antibodies(TRBAb) are produced which also plays an important role in 
pathogenesis of graves disease.  
CLINICAL FEATURES: 
Symptoms include hyperactivity, altered mood, irritability, increased 
sweating, heat intolerance. They may have dyspnea, fatigue, weight loss with 
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increased appetite.  Signs include warm moist skin, sinus tachycardia, atrial 
fibrillation, palmar erythema, muscle weakness and wasting and high output 
cardiac failure.  
Manifestations of graves disease include diffuse goiter, ophthalmopathy, 
thyroid acropachy, lymphoid hyperplasia 
Conditions associated with graves disease include Addison disease, type 
1 diabetes mellitus, perinicious anemia, vitiligo, and myasthenia gravis.   
LABORATORY FINDINGS:  
Thyroid function tests reveals elevated T4 (thyroxine), T3 (tri-
iodothyronine), free T3 and free T4 levels and TSH remains suppressed. 
Antithyroid antibodies include thyroid peroxidase antibodies[32] and TRSAb are 
often present. Thyroid receptor stimulating antibodies. measurement is helpful 
in confirming the diagnosis and its disappearance predicts remission of the 
disease.  Radioiodine studies are rarely indicated.  Affected young children 
often have advanced skeletal maturation and craniosynostosis.  
TREATMENT: 
Antithyroid drugs are the recommended initial therapy in young 
children. The antithyroid drugs which is used commonly is propylthiouracil 
and methimazole. The mechanism of action of these drugs is inhibition of 
incorporation of trapped inorganic iodide into organic compounds. They also 
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suppresses the TRSAb levels by directly affecting the intrathyroidal 
autoimmunity.  
ANTITHYROID DRUGS 
Compared to propylthiouracil, methimazole[32] is 10 times more potent 
drug and have long  half life(6-8hrs vs 0.5hr). Propylthiouracil is highly protein 
bound and do not cross placenta and lesser ability to pass into breast milk.  
Therefore propylthiouracil is the preferred drug during pregnancy and nursing 
women. Propylthiouracil is preferred in neonatal thyrotoxicosis due to 
inhibition of extrathroidal conversion of T4 to T3.  
Adverse reactions with antithyroid drugs are not uncommon,but usually 
mild and severe reactions is very rare. The side effects are usually 
unpredictable and can occur after any duration of therapy.  Transient 
agranulocytopenia and urticarial rashes are very common and does not warrant 
discontinuation of treatment. The severe adverse reactions include hepatitis, 
agranulocytosis, vasculitis, lupus like polyarthritis syndrome and aplasia cutis 
congenital.  
The initial starting dose of propylthiouracil is 5-10mg/kg/day given 
three times daily and methimazole in dosage of 0. 25-1. 0 mg/kg/day given as 
single dose. Clinical response is evident in 6 wk and control is achieved in 3-4 
months. The drug is tapered slowly to maintain the euthyroid state. Antithyroid 
drugs may be required for 5 years or longer because the remission rate is 25% 
every 2years. Relapses are not uncommon and uaually occurs within 6 months 
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of discontinuation of therapy. Propranolol in dose of 0. 5-2. 0mg/kg/day is 
useful in management of severe toxic patients along with antithyroid drugs.  
If medical treatment fails or when there is severe adverse effects,surgery 
or radioiodine treatment is indicated. Once the euthyroid state is 
attained,subtotal thyroidectomy can be done which is highly effective.  
Propylthiouracil or methimazole for 2-3 months before surgery results in 
euthyroid state. After achieving euthyroid state, potassium iodide solution 5 
drops/24hr for 2 weeks before surgery results in decreased vascularity of the 
gland.  
Radioiodine therapy is an alternative effective first line therapy in 
children over 10years of age with graves disease. Antithyroid drugs are stopped 
a week before radioiodine therapy. The radioiodine dose for complete ablation 
of thyroid gland is 300uCi/g or 15mCi. Almost all patients with this 
radioiodine therapy will achieve hypothyroidism in about 9 to 28 weeks. 
9(average 11wk). The ophthalmopathy undergoes gradual remission which is 
independent of the hyperthyroidism. High dose prednisolone, orbital 
radiotherapy and orbital decompression surgery are the therapeutic options for 
severe graves ophthalmopathy.  
 
CONGENITAL HYPERTHYROIDISM: 
 
ETIOLOGY: 
  
Transplacental passage of TRSAb from mother to fetus causes neonatal 
graves disease but the onset and clinical course is modified by the concurrent 
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passage of thyroid receptor blocking antibodies(TRBAb) and the antithyroid 
medications taken by the mother. Classical congenital hyperthyroidism is due 
to very high levels of thyroid receptor stimulating antibodies.  The mothers of 
these affected neonates usually have graves disease. The incidence of neonatal 
graves disease is about 2% to the mother with graves disease. It is more 
common in boys than girls unlike other thyroid disease.  
CLINICAL FEATURES: 
Affected newborns are usually premature and there is intrauterine 
growth retardation. Fetal goiter will be present in most of the affected babies. 
The newborn is irritable,restless and hyperactive. They may have triangular 
facies,exophthalmic wide open eyes, frontal bossing, craniosynostosis and 
microcephaly are common. Tachycardia,tachpnea,hyperthermia,weight loss 
and hepatosplenomegaly are other common clinical features. Cardiac 
decompensation and severe hypertension can occur rarely in some infants. 
Thyroid function tests reveal high T4 and T3 level with suppressed TSH levels.  
TREATMENT: 
Propranolol administered orally in dose of 1-2 mg/kg/day along with 
propylthiouracil in dose of 5-10 mg/kg/day or methimazole remains the 
cornerstone therapy. Parenteral fluid therapy and corticosteroids are indicated 
in severe thyrotoxic state. Digitalization is necessary in heart failure cases. 
Neonatal graves disease usually remits spontaneously in 6-12 weeks but it may 
persists for longer periods which depends on level of TRBAb.  
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THYROID HORMONE STUDIES: 
To measure the thyroid hormones in serum, there are number of newer 
generation thyroid assay is available at present and so it is possible to measure 
T4, free T4,T3 and freeT3 and reverse T3. Reverse T3 (3,5’,3’-
triiodothyronine) is the metabolically inert thyroid hormone fraction.  
Thyroglobulin[23] is a glycoprotein dimer which is present in the colloid 
secreted through the apical surface of thyrocyte membrane. Smaller amount of 
thyroglobulin escapes from the colloid into the circulation which is measurable 
in serum. TSH stimulation increases the thyrotropin levels in serum and 
decrease with TSH suppression. Thyrotropin levels are elevated in newborns, 
graves disease patients,endemic goiter and in autoimmune thyroid disease. 
Differentiated carcinoma of thyroid is associated with very high levels of 
thyrotropin in serum.  
Measurement of TSH levels remains an extremely sensitive indicator for 
primary hypothyroidism. The newer generation sensitive TSH assays obviate 
the need for TRH stimulation in the diagnosis of thyroid disorder. The normal 
levels of TSH after the neonatal period is less than 6Uu/Ml.  
FETAL AND NEWBORN THYROID HORMONE PHYSIOLOGY: 
From midgestation fetal T4 level increases progressively to attain a level 
of 11. 5ug/dl at term. On the otherhand fetal T3 hormone level is low before 20 
weeks of gestation and then increases gradually to about 45ng/dl. The inactive 
form of t3(reverse T3) in contrast to T4 is high in the fetus (250ng/dl at 30 
  37
weeks) and then decreases gradually to 150ng/dl. At term the TSH level rises to 
about 10 mu/L. One third of maternal T4 crosses placenta to the fetus. `The 
transplacentally transferred T4 hormones play a pivotal role in the fetal 
development especially brain. Therefore hypothyroid fetus are at risk for 
neurologic damage. But the amount of T4 hormone that crosses the placenta is 
insufficient to interfere in making diagnosis of congenital hypothyroidism.  
There is an acute release of TSH after birth and it reaches a peak 
concentration of about 60 mu/l in 30 min in a full term infant[1,19]. There is a 
rapid decline within 24hrs and then a gradual decline over next 5 days to less 
than 10uu/ml. The acute rise in TSH produces an increase in T4 levels to about 
16ug/dl and t3 to approximately 300ng/dl in about 4 hours. In the next 2 weeks 
of life there is a gradual decline of T4 to about 12ug/dl and T3 to level of 
200ng/ml[1]. Serum free T4 levels is 0. 9-2. 3ng/dl in infancy and decreases 
gradually to 0. 7-1. 8ng/dl in childhood and the corresponding free T3 levels to 
about 540pg/dl in infancy and is 210-440pg/dl in childhood. Reverse t3 level is 
200ng/dl in 2wk and declines to 50ng/dl in 4 weeks. [1] 
THYROID FUNCTION IN PRETERM BABIES: 
It is qualitatively similar but quantitatively lower when compared to 
term babies[19]. In proportion to gestational age and birthweight, cord blood 
TSH varies. Compared to term babies,the postnatal TSH surge is reduced and 
serum T4 level is low in first week of life in newborn with extreme prematurity 
and complications like respiratory distress. The serum T4 levels gradually 
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increase and by 6 weeks of life it reaches T4 range as that of term babies. 
Serum T4 concentrations are the least affected parameter in preterm babies. 
There is high frequency of transient TSH elevations and so they have high 
incidence of transient primary hypothyroidism. The combination of immature 
hypothalamic-pituitary thyroid axis and inadequate maternal transplacental 
transfer of thyroid hormones makes the extreme preterm infant at risk for 
congenital hypothyroidism.  
SERUM THYROXINE BINDING GLOBULIN: 
It is a glycoprotein which is synthesized in the liver which binds to 
thyroid hormone and helps in transportation.  Thyroid binding globulin[23] is 
increased or decreased in variety of clinical situations with effects on the level 
of total thyroxine. TBG (thyroid binding globulin) binds to 70% of T4 and 50% 
of T3. The conditions associated with increase in TBG levels are newborn 
period, pregnancy, drugs like heroin,oral contraceptives and perphenazine. 
Androgens, anabolic steroids, glucocorticoids and l-asparaginase associated 
with decrease in TBG levels. TBG levels will be low in liver disease, protein 
losing enteropathies and congenital nephritic syndrome.  
RADIONUCLIDE STUDIES: 
By measuring the uptake of radioactive isotope (123I) we can evaluate 
the concentrating or trapping function of thyroid gland. Technetium (99Mt)[15] 
in contrast to iodine, it is trapped but not organified in the thyroid with half life 
of 6 hours. To assess the presence of thyroid tissue in situations like thyroid 
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agenesis and ectopic thyroid gland, thyroid scanning will be useful and also to 
evaluate the possible ‘hot’ thyroid nodules.  Iodine131 scaning is limited in 
children due to risk of thyroid cancer.  
THYROID ULTRASONOGRAPHIC STUDIES: 
It helps in assessing the location, shape and size of thyroid gland and to 
evaluate the cystic or solid nature of nodules. Thyroid ultrasound reveals 
scattered hypoechogenicity in case of autoiimune thyroiditis. To assess the 
goiter size and to assess the thyroid nodules thyroid ultrasound is more accurate 
than physical examination. It is not reliable in evaluating thyroid dysgenesis[32] 
particularly ectopic thyroid gland compared to radionuclide studies.  
DEFECTS OF THYROXINE BINDING GLOBULIN(TBG): 
They are not associated with clinical disease and does not require 
treatment. They are identified by a chance finding of abnormally high or low 
levels of thyroxine(T4).  This condition rather will make confusion in diagnosis 
of hypothyroidism or hyperthyroidism.  
CONGENITAL TBG DEFICIENCY:  
It is transmitted as an X linked dominant disorder[23] and occurs in 1: 
2400 male newborns. TBG is identified incidentally in neonatal thyroid 
screening which uses T4 levels as the primary screen.  These patients have low 
levels of T4 hormone and high RT3U (resin triiodothyronine uptake) but TSH 
levels and free T4 levels are normal.  Confirmation of diagnosis is by finding 
low or absent levels of TBG[23]. Complete thyroid binding globulin deficiency 
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(<5ug/dl) is very rare. Acquired thyroid binding globulin deficiency is 
associated with glucocorticoids and androgen treatment, hepatic insufficiency, 
proteinuria, and renal insufficiency.   
Thyroid binding globulin excess is an X linked disorder and is identified 
particulary in adults.  T4 level is high and T3 is variably elevated, RTU3is 
elevated but free T4 level is normal. Confirmation of diagnosis is by 
demonstrating the elevated levels of thyroid binding globulin. The affected 
patients are clinically euthyroid. The acquired cause for TBG deficiency is 
pregnancy, hepatitis, estrogen treatment and drugs like perphenazine,clofibrate 
and methadone.  
FAMILIAL DYSALBUMINEMIC HYPERTHYROXINEMIA: 
It is an autosomal disorder, when present it may be confused with 
diagnosis of hyperthyroidism. The basic pathophysiology is increased binding 
of T4 to an abnormal albumin variant. This results in high T4 levels but free 
T3,free T4 and TSH levels are normal. Affected patients are euthyroid 
clinically.  
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MATERIALS AND METHODS 
This is a descriptive analytical study which was performed in kilpauk 
medical college during a period of 6 months period and 110 newborn cord 
blood sample was collected and analysed.  Blood samples were drawn from 
maternal end of cord immediately after the cord is being cut and about 2ml of 
blood is collected. The sample thus collected was kept at room temperature of 
around 25C and transported to laboratory within 4 hour and then sample 
analyzed with electrochemiluminence assay. The data of each child will be 
collected in the specific proforma which includes the newborn name,gestational 
age, sex, birth weight,requirement of resuscitation,apgar score,weight 
appropriate for gestation,parity of mother, gestational diabetes mellitus and 
mode of delivery.  
Cord blood TSH levels are measured using electro-chemi-luminescence 
immunoassay. The mean TSH levels are calculated and effect of perinatal 
factors on cord blood TSH levels are analysed statistically. All neonates who 
had TSH level above the cut off values are repeated TSH levels in venous 
sample on 5th day of life.  
INCLUSION CRITERA 
• All consecutive live births delivered in hospital during study period(6 
months) with informed parental consent 
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EXCLUSION CRITERIA 
• Neonates whose mothers were on any known antithyroid drugs.  
• Those with antenatal detected CNS malformations and major life 
threatening malformation.  
JUSTIFICATION OF STUDY 
Cord blood TSH has high sensitivity but with a high false positive 
values and a wide range of values causes high recall rates requiring evaluation 
for confounding factors contributing to increase in TSH values. Postnatal surge 
in TSH levels common to all newborns is considered to be mediated through 
alpha adrenergic stimulation following cold stress. Also various maternal and 
perinatal factors are known to affect cord blood TSH levels.  In the present 
study nine factors included are 1)parity of mother 2) gestational diabetes 
mellitus 3)mode of delivery 5)birth weight 6)gestational age 7)sex 8)weight 
appropriate for gestation 9)requirement of resuscitation 9) apgar score 
STUDY DESIGN - descriptive cross sectional study 
STUDY PERIOD: 6 MONTHS 
SAMPLE SIZE 
Calculation of sample size to study 10 factors in multiple regression 
model with 
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•       N= (Z1-α/Z)² σ² 
                                   d² 
• N=sample size 
• Z1-α/Z=1. 96 for d=0. 05 
• d= precision (relative)=20% of σ 
• σ=standard deviation=9 
• =   1. 96×1. 96×9×9 
                  0. 2×9×0. 2×9 
• Sample size is 110 
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TABLE 3: GESTATIONAL AGE 
 
 
GESTATION
AL AGE Frequency Percent 
 TERM 74 67. 3 
PRETERM 36 32. 7 
Total 110 100. 0 
 
 
 Among 110 cord blood samples 74 samples are from term babies and 
36 samples from preterm babies selected in a random manner.  
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TABLE 5 :MODE OF DELIVERY 
  Frequency  Percent 
 OTHER MODE OF 
DELIVERY 
97 88. 2 
EMERGENCY LSCS 13 11. 8 
Total 110 100. 0 
 
 
 
Among 110 cord blood samples, 13 from emergency lscs delivery and 
97 from other mode of deliveries (vaginal, elective lscs, vacuum) in a random 
manner.  
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TABLE 9: RELATIONSHIP OF PARITY WITH CORD BLOOD TSH 
Group Statistics 
 Parity of 
mother N Mean 
Std.  
Deviation 
Std.  Error 
Mean 
P 
 
TSH value  
( mIU/mL) 
MULTIPAR
OUS 
70 10. 3068 5. 64361 . 67454 0. 507. 
NULLIPAR
OUS 
40 10. 0490 5. 59443 . 88456 
 
On evaluating the variable, the parity of mother with cord blood TSH 
among 110 samples, the mean among multiparous women in 70 sample is 
found to be 10. 3068 and for nulliparous it is 10. 049 out of 40 sample.  The p 
value is derived which is found to be 0.507 which is statistically not significant.  
TABLE 10: RELATIONSHIP OF GDM WITH  
CORD BLOOD TSH LEVELS 
Group Statistics 
 
 
 
GDM N Mean Std.  
Deviation 
Std.  Error 
Mean 
P VALUE
TSH value ( 
mIU/mL) 
GDM 15 11. 
0935
5. 99576 1. 54810 
NO 
GDM 
95 10. 
0740
5. 55746 . 57018 0. 515
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On evaluating the relationship of gestational diabetes mellitus with cord 
bloos TSH levels, the mean value is 11. 093 among 15 mother with GDM and 
10. 074 among 95 mother with no history of GDM. The P value derived is  
0. 515 which is statistically not significant.   
TABLE 11: RELATIONSHIP OF GESTATIONAL  
AGE WITH CORD BLOOD TSH 
      Group Statistics 
 Gestational 
age 
N Mean 
Std.  
Deviation 
Std.  Error 
Mean 
P 
VALUE
TSH value  
( mIU/mL) 
PRETERM 36 10. 0798 6. 28795 1. 04799 
TERM 74 10. 2778 5. 28008 . 61380 0. 863
 
On evaluating the relationship of the variable, gestational age among 
110 samples, the standard deviation derived from 36 preterm sample is 10. 
0798 and among 74 term baby sample it is 10. 2778.  The P value hence 
derived is 0. 863 which is statistically insignificant.  
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TABLE 12: RELATIONSHIP OF WEIGHT APPROPRIATE FOR 
GESTATIONAL AGE WITH CORD BLOOD TSH 
      Group Statistics 
 Weight 
appropriate 
for gestation
Std.  
Deviation 
Std.  Error 
Mean P value 
TSH value  
( mIU/mL) 
SGA 5. 08706 1. 35957 0. 453
AGA 5. 68072 . 57979 
 
On evaluating the relationship of the variable, weight appropriate for 
gestation, the standard deviation among 14 samples from SGA babies are found 
to be 5. 08706 and is 5. 6807 among 96 AGA babies sample. The P value 
derived is 0. 453 which is statistically insignificant.   
TABLE 13: RELATIONSHIP OF MODE OF  
DELIVERY AND CORD BLOOD TSH 
Group 
Statistics Mode of delivery N Mean 
Std.  
Deviation
Std.  Error 
Mean P value 
TSH value ( 
mIU/mL) 
EMERGENCY LSCS 13 17. 9777 5. 83681 1. 61884 
OTHER MODE OF 
DELIVERY 
97 9. 1724 4. 70189 . 47740 0. 0001
 
On evaluating the relationship of mode of delivery with cord blood TSH 
among 110 samples, the standard deviation found to be 17. 977 among 13 
deliveries with emergency lscs and 9. 172 among other modes of delivery 
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including vaginal, elective cesarean and vacuum delivery.  The P value 
henceforth derived is 0. 0001 which is statistically significant.  
TABLE 14: RELATIONSHIP BETWEEN APGAR  
SCORE AND CORD BLOOD TSH LEVELS 
Group Statistics 
 
Apgar N Mean 
Std.  
Deviation 
Std.  Error 
Mean 
P value 
TSH value  
(mIU/mL) 
<7 10 15. 7020 7. 83595 2. 47795 0. 0259 
7 AND 
ABOVE 
100 9. 6641 5. 06118 .50612  
 
On evaluating the relationship between apgar scores and TSH levels in 
cord blood of 110 samples, the standard deviation found is 15. 702 among 10 
babies whose apgar score less than 7.  Among 100 babies with apgar scores 
above 100 the standard deviation derived is 5. 0611.  The P value derived from 
above relationship isa 0. 0259 (p< 0. 05) which is statistically significant.  
TABLE 14:RELATIONSHIP OF  
RESUSCITATION WITH TSH LEVELS 
 Requirement of 
resuscitation N Mean 
TSH value  
( mIU/mL) 
RESUSCITATION 
REQUIRED 
8 17. 5863
NO RESUSCITATION 
REQUIRED 
102 9. 6347
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 Requirement of 
resuscitation 
Std.  
Deviation
Std.  Error 
Mean P value 
TSH value  
( mIU/mL) 
RESUSCITATION 
REQUIRED 
8. 68663 3. 07119 0. 0292
NO RESUSCITATION 
REQUIRED 
4. 89771 . 48495 
 
On evaluating the relationship between the variable, requirement of 
resuscitation with cord blood TSH levels, the standard deviation derived among 
8 babies who required resuscitation is 8. 6866 and for 102 babies without 
resuscitation is 4. 8971. The P value found to be 0. 0292 (p < 0. 05) which is 
statistically significant.  
TABLE 15: RELATIONSHIP BETWEEN  
GENDER AND TSH LEVELS 
Group Statistics 
 
Sex N Mean Std.  Deviation
Std.  Error 
Mean P value 
TSH value  
( mIU/mL) 
FEMALE 45 10. 4913 5. 79162 . 86336 0. 667
MALE 65 10. 0204 5. 50311 . 68258 
 
On evaluating the relationship between the gender variable and cord 
blood TSH levels the standard deviation derived is 5.791 among 45 female 
babies and 5.5031 among 65 male babies. The P value is found to be 0.667 
which is insignificant statistically.  
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TABLE 16: RELATIONSHIP BETWEEN WEIGHT  
APPROPRIATE FOR GESTATION AND TSH LEVELS 
Group Statistics 
Weight 
appropriate 
for gestation
Std.  
Deviation 
Std.  Error 
Mean P VALUE 
TSH value  
(mIU/mL) 
SGA 5. 08706 1. 35957 0. 453
AGA 5. 68072 . 57979 
 
On evaluating the relationship between the variable, weight appropriate 
for gestation and TSH levels the standard deviation found to be 5. 0870 for 
SGA babies and 5. 6807 among AGA babies. The P value found to be 0. 453 
which is insignificant statistically 
TABLE 17: ROC CURVE FOR TSH VALUES WITH  
RESPECT TO FOLLOWING VARIABLES 
VARIABLE SENSITIVITY 
SPECIFI
CITY AUC 
CRITERI
ON P VALUE SIG 
RESUSCITATION 75 89. 2 0. 776348 >15. 1 0. 0292 YES 
EMERGENCY 
LSCS 
84. 6 88. 7 0. 896511 >13. 1 <0. 0001 YES 
APGAR 70 85 0. 737500 >13. 1 0. 0259 YES 
BIRTH WEIGHT 48 74. 1 0. 571765 >11. 33 0. 2463 NO 
GDM 86. 7 29. 5 0. 543860 >6. 54 0. 5940 NO 
GES. AGE 63. 89 56. 76 0. 559685 ≤8. 32 0. 3341 NO 
PARITY 34. 29 85 0. 513571 >11. 9 0. 8102 NO 
WEIGHT 
APPROPRIATE 
64. 3 75 0. 597842 >11. 5 0. 2577 NO 
SEX 42. 22 72. 31 0. 512137 >10. 5 0. 8338 NO 
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On evaluating the relationship between cord blood TSH levels and the 
categorical variables there is significant relationship between emergency lscs 
and cord blood TSH level(p value <0. 001), resuscitation and cord blood TSH 
(P value 0. 0292) and low apgar value and cord blood TSH (p value< 0. 0259).  
The other variables considered in the study which includes gender, parity of 
mother, birth weight, weight appropriate for gestation, gestational age does not 
have significant p values and are considered as statistically insignificant.  
ROC curve 
 
Variable TSH_value___mIU_mL_ 
TSH value ( mIU/mL) 
Classification variable Apgar 
  
Sample size   110
Positive group :  Apgar = 1 10
Negative group :  Apgar = 0 100
  
Disease prevalence (%) 9. 09
  
Area under the ROC curve (AUC)  
  
Area under the ROC curve (AUC) 0. 737500
Standard Errora 0. 107
95% Confidence intervalb 0. 645006 to 0. 816789
z statistic 2. 228
Significance level P (Area=0. 5) 0. 0259
 
Youden index 
  
Youden index J 0. 5500 
Associated criterion >13. 1 
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APGAR ROC CURVE 
 
   
On plotting the ROC curve with respect to cord blood TSH, sensitivity 
is found to be 70. 0% and specificity is 85. 0% and the criterion cut off is  
>13. 1 
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RESUSCITATION ROC 
 
ROC curve 
Variable TSH_value___mIU_mL_ 
TSH value ( mIU/mL) 
Classification variable Requirement_of_resuscitation 
Requirement of resuscitation 
  
Sample size   110 
Positive group :  Requirement of resuscitation = 1 8 
Negative group :  Requirement of resuscitation = 0 102 
  
Disease prevalence (%) 7. 27 
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Area under the ROC curve (AUC)  
  
Area under the ROC curve (AUC) 0. 776348 
Standard Errora 0. 127 
95% Confidence intervalb 0. 686995 to 0. 850282 
z statistic 2. 180 
Significance level P (Area=0. 5) 0. 0292 
  
Youden index 
  
Youden index J 0. 6422 
Associated criterion >15. 1 
  
 
MODE OF DELIVERY
 
TSH value ( mIU/mL)
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ROC curve 
Variable TSH_value___mIU_mL_ 
TSH value ( mIU/mL) 
Classification variable Mode_of_delivery 
Mode of delivery 
  
Sample size   110 
Positive group :  Mode of delivery = 1 13 
Negative group :  Mode of delivery = 0 97 
  
Disease prevalence (%) 11. 8 
  
Area under the ROC curve (AUC)  
  
Area under the ROC curve (AUC) 0. 896511 
Standard Errora 0. 0375 
95% Confidence intervalb 0. 823908 to 0. 946471 
z statistic 10. 562 
Significance level P (Area=0. 5) <0. 0001 
 
 Youden index 
  
Youden index J 0. 7328 
Associated criterion >13. 1 
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BIRTH WEIGHT ROC CURVE 
 
ROC curve 
Variable TSH_value___mIU_mL_ 
TSH value ( mIU/mL) 
Classification variable Birth_weight 
Birth weight 
  
Sample size   110 
Positive group :  Birth weight = 1 25 
Negative group :  Birth weight = 0 85 
  
Disease prevalence (%) 22. 7 
  
TSH value ( mIU/mL)
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 Criterion : >11.33
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Area under the ROC curve (AUC)  
  
Area under the ROC curve (AUC) 0. 571765 
Standard Errora 0. 0619 
95% Confidence intervalb 0. 473885 to 0. 665682 
z statistic 1. 159 
Significance level P (Area=0. 5) 0. 2463 
 
 Youden index 
  
Youden index J 0. 2212 
Associated criterion >11. 33 
  
 
 
GESTATIONAL DIABETES MELLITUS ROC CURVE 
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ROC curve 
Variable TSH_value___mIU_mL_ 
TSH value ( mIU/mL) 
Classification variable GDM 
  
Sample size   110 
Positive group :  GDM = 1 15 
Negative group :  GDM = 0 95 
  
Disease prevalence (%) 13. 6 
  
Area under the ROC curve (AUC)  
  
Area under the ROC curve (AUC) 0. 543860 
Standard Errora 0. 0823 
95% Confidence intervalb 0. 446157 to 0. 639142 
z statistic 0. 533 
Significance level P (Area=0. 5) 0. 5940 
  
Youden index 
  
Youden index J 0. 1614 
Associated criterion >6. 54 
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GESTATIONAL AGE ROC CURVE 
 
ROC curve 
Variable TSH_value___mIU_mL_ 
TSH value ( mIU/mL) 
Classification variable Gestational_age 
Gestational age 
  
Sample size   110 
Positive group :  Gestational age = 1 36 
Negative group :  Gestational age = 0 74 
  
Disease prevalence (%) 32. 7 
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Area under the ROC curve (AUC)  
  
Area under the ROC curve (AUC) 0. 559685 
Standard Errora 0. 0618 
95% Confidence intervalb 0. 461846 to 0. 654229 
z statistic 0. 966 
Significance level P (Area=0. 5) 0. 3341 
  
Youden index 
  
Youden index J 0. 2065 
Associated criterion ≤8. 32 
  
 
PARITY ROC CURVE: 
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ROC curve 
Variable TSH_value___mIU_mL_ 
TSH value ( mIU/mL) 
Classification variable Parity_of_mother 
Parity of mother 
  
Sample size   110 
Positive group :  Parity of mother = 1 70 
Negative group :  Parity of mother = 0 40 
  
Disease prevalence (%) 63. 6 
  
Area under the ROC curve (AUC)  
  
Area under the ROC curve (AUC) 0. 513571 
Standard Errora 0. 0565 
95% Confidence intervalb 0. 416386 to 0. 610008 
z statistic 0. 240 
Significance level P (Area=0. 5) 0. 8102 
a DeLong et al., 1988 
b Binomial exact 
  
Youden index 
  
Youden index J 0. 1929 
Associated criterion >11. 9 
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 WEIGHT APPROPRIATE FOR GESTATION ROC CURVE 
 
 
ROC curve 
Variable TSH_value___mIU_mL_ 
TSH value ( mIU/mL) 
Classification variable Weight_appropriate_for_gestation 
Weight appropriate for gestation 
  
Sample size   110 
Positive group :  Weight appropriate for gestation = 1 14 
Negative group :  Weight appropriate for gestation = 0 96 
  
Disease prevalence (%) 12. 7 
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Area under the ROC curve (AUC)  
  
Area under the ROC curve (AUC) 0. 597842 
Standard Errora 0. 0864 
95% Confidence intervalb 0. 500061 to 0. 690219 
z statistic 1. 132 
Significance level P (Area=0. 5) 0. 2577 
  
Youden index 
  
Youden index J 0. 3929 
Associated criterion >11. 5 
  
 
GENDER ROC CURVE 
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ROC curve 
Variable TSH_value___mIU_mL_ 
TSH value ( mIU/mL) 
Classification variable Sex 
  
Sample size   110 
Positive group :  Sex = 1 45 
Negative group :  Sex = 0 65 
  
Disease prevalence (%) 40. 9 
  
Area under the ROC curve (AUC)  
  
Area under the ROC curve (AUC) 0. 512137 
Standard Errora 0. 0578 
95% Confidence intervalb 0. 414984 to 0. 608619 
z statistic 0. 210 
Significance level P (Area=0. 5) 0. 8338 
  
Youden index 
  
Youden index J 0. 1453 
Associated criterion >10. 5 
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DISCUSSION 
Our hypothesis is to evaluate the mean TSH levels and various perinatal 
factors affecting the TSH levels in the cord blood of newborn.  There are many 
perinatal factors during the delivery affect the TSH levels but in our study 
emergency LSCS, resuscitation and apgar score are the variables that have 
significant statistical relationship with cord blood TSH. The exact reason for 
this condition has not been found yet; but possibly can be explained by stress 
events during labour and pregnancy. From the previous tables we conclude that 
the variables such as emergency LSCS, low apgar scores and babies who 
required resuscitation are having statistically significant elevated cord blood 
TSH levels.  
The other perinatal variables such as gestational age, parity of mother, 
sex of the newborn, gestational diabetes mellitus, weight appropriate for 
gestation doesnot have significant TSH elevations and their P values remains 
insignificant. Furthermore to strengthen our hypothesis, the cross tables, ROC 
curves and cut off criterion of all perinatal outcome is being presented.  
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VARIABLE SENSITIVITY 
SPECIFICI
TY AUC 
CRITERIO
N 
P 
VALUE SIG 
RESUSCITATI
ON 
75 89. 2 0. 
776348 
>15. 1 0. 0292 YES 
EMERGENCY 
LSCS 
84. 6 88. 7 0. 
896511 
>13. 1 <0. 
0001 
YES 
APGAR 70 85 0. 
737500 
>13. 1 0. 0259 YES 
BIRTH 
WEIGHT 
48 74. 1 0. 
571765 
>11. 33 0. 2463 NO 
GDM 86. 7 29. 5 0. 
543860 
>6. 54 0. 5940 NO 
GES. AGE 63. 89 56. 76 0. 
559685 
≤8. 32 0. 3341 NO 
PARITY 34. 29 85 0. 
513571 
>11. 9 0. 8102 NO 
WEIGHT 
APPROPRIATE 
64. 3 75 0. 
597842 
>11. 5 0. 2577 NO 
SEX 42. 22 72. 31 0. 
512137 
>10. 5 0. 8338 NO 
 
From the above table the variables such as mother who had emergency 
lscs, babies with low apgar scores and baby who are resuscitated follows the 
same line of significant P values, area under curve, ROC cut off criterian. The 
other perinatal factors doesnot have statistically significant area under curve 
and P values.  
 
The variables such as requirement of resuscitation, emergency lscs and 
apgar scores were having direct correlation with the elevation of TSH levels in 
cord blood. Then we have taken venous sample for newborn with TSH value 
more than 13. 1 (cut off values from ROC curve) at 5th day of life. Then paired 
t-test done for the initial and venous blood TSH values and finding out the 
statistical significance.  It is found to be low and this falsely elevated TSH 
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levels is due to perinatal stress factors which also supported by other previous 
journals done in different centres.  
There are some studies which have been performed in this same  
field, in which some are supporting and some results are controversial. 
Herbstman et al., study performed in 300 newborns revealed that several 
factors such as maternal age,pregnancy induced hypertension, gestatational 
diabetes mellitus and mode of delivery can affect thyroid hormone status which 
is inconsistent with our study.  
Kim et al., study of perinatal factors affecting cord blood TSH levels 
performed in 130 neonates in korea revealed that perinatal stress events 
significantly affect cord blood TSH levels. Amit gupta et al., study revealed 
that there was no significant difference in cord blood TSH between male and 
female babies which is consistent with our study. + 
 
Various studies are using different cut-offs for CBTSH levels ranging 
from 20-90 Miu/ml.  We have used the cut-off value for cord blood TSH level 
as per ROC curve is 13. 1u/ml.  Devi AR and Noushad et al.,[45] has taken the 
following range for comparison-CBTSH value <10uu/ml as normal,10-20uu/ml 
as borderline and >20uu/ml as abnormal. Gurjit kaur et al., from Chandigarh 
has taken 9uu/ml as the TSH cut off value. Ruth V Mikelsaar et al.,[48] from 
Estonia has taken CBTSH cut off value of 12uu/ml which is lower cut off value 
when compared to our study.   
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In our study 20 cord samples among 110 samples are found to have 
CBTSH levels above the cut off value of 13. 1 and repeat venous sampling 
done on 5th day of life.  All venous samples TSH levels found to be lower than 
cut off TSH levels.  This reveals that the high cord blood TSH levels are due to 
perinatal stress factors such as emergency LSCS,resuscitation and low apgar 
score which has significant positive correlation as evidenced with P values in 
our study.  
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LIMITATIONS IN THE STUDY: 
To have more conclusive evidence of our findings, 
1.  We have to evaluate large number of babies 
2.   To include other maternal and perinatal factors in the analysis.  
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CONCLUSION OF THE STUDY 
As we know that congenital hypothyroidism is the most common 
preventable cause for mental retardation with an incidence of 1:3000-1:4000[1] 
live births worldwide and about 1:2500-2800 in India. Therefore neonatal 
screening for congenital hypothyroidism is very essential using TSH levels 
either in cord blood or heel prick sample. Cord blood TSH level hence an 
accepted tool for screening.  But it is limited by the fact, that the cord blood 
TSH have high sensitivity but with high false positive values due to 
confounding factors. There are various perinatal factors affects cord blood TSH 
levels. In our study emergency lscs,low apgar score and requirement of 
resuscitation affects cord blood TSH levels.  
RECOMMENDATIONS: 
As various perinatal factors influence cord blood TSH levels, knowledge 
about these factors helps in reliable interpretation of the results and any rise in 
TSH should be seen in the light of these factors.  This helps in avoiding 
unnecessary repeat evaluation and hence this will saves cost as well as the need 
to subject for invasive investigations.  
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ANNEXURE-1:  PROFORMA 
ANNEXURE-2:  PATIENT CONSENT FORM 
ANNEXURE 3: LIST OF ABBREVIATIONS 
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PROFORMA 
NAME: 
AGE: 
SEX: 
B. WT: 
WT APPROPRIATE FOR GESTATION: 
APGAR SCORE: 
REQUIREMENT FOR RESUSCITATION: 
PARITY OF MOTHER: 
GESTATIONAL DIABETES MELLITUS: 
MODE OF DELIVERY: 
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LIST OF ABBREVIATIONS USED 
TSH Thyroid Stimulating Hormone 
TRH  Thyrotropin Releasing Hormone 
MIT Mono-Iodo Thyronine 
DIT Di-Iodo Thyronine 
TRSAb Thyroid Receptor Stimulating Antibody 
TRBAb Thyroid Receptor Blocking Antibody 
TPOAb Thyroid Antiperoxidase Antibody 
TRSI Thyroid Receptor Stimulating Immunoglobulin 
TBG Thyroid Binding Immunoglobulin 
 
 
 
 
 


S No Name Parity of moGDM Gestational ageWeight apprMode of delBirth weightSex
1 b/o rajeshwari 0 1 0 0 0 0 0
2 b/o manimegal 1 0 0 0 0 0 1
3 b/ovimala 1 0 0 0 0 0 0
4 b/odhatchayani 0 0 1 1 0 1 0
5 b/osujithra 1 0 0 0 1 0 0
6 b/o kavitha 1 0 0 0 0 0 1
7 b/oprema 1 0 0 0 0 1 0
8 b/opushpa 1 0 0 0 1 0 1
9 b/o mahalakshm 0 0 1 0 0 0 0
10 b/okavitha 1 0 0 1 0 0 1
11 b/orani 1 0 1 0 0 0 0
12 b/ogayathri 0 0 0 0 0 0 0
13 b/o raja karth 1 0 0 0 0 0 1
14 b/otamilmala 0 1 0 0 0 0 0
15 b/okanmani 1 0 1 0 0 1 1
16 b/o surya 0 0 0 0 1 0 1
17 b/o amutha 1 0 1 1 0 1 1
18 b/okeerthan 1 0 0 0 0 0 0
19 b/oshameem 1 0 1 0 0 1 1
20 b/o kamatchi 0 0 0 0 0 0 0
21 b/osridevi 1 0 0 0 0 0 0
22 b/opanimala 1 1 1 0 1 0 1
23 b/odeepa 0 0 0 1 0 0 0
24 b/okannagi 1 0 0 0 0 1 1
25 b/ojeyarani 1 0 1 1 0 1 1
26 b/omuniyam 1 0 1 0 0 1 0
27 b/o rajaman 1 1 1 0 0 0 0
28 b/ojeeva 1 0 0 0 0 0 1
29 b/o sameera 0 0 0 0 0 0 0
30 b/okanimozh 0 1 1 0 0 0 1
31 b/o meena 0 0 0 0 0 0 1
32 b/o ranjitham 1 0 0 1 0 1 0
33 b/o banu 0 0 0 0 0 0 0
34 b/o thangam 0 0 0 0 0 0 0
35 b/o chellamal 1 0 0 1 0 1 1
36 b/o poovathal 0 0 0 0 0 0 1
37 b/operiynayagi 1 0 1 0 0 0 0
38 b/o seetha 0 0 0 0 0 0 0
39 b/opalaniamm 1 0 0 0 1 0 0
40 b/o geethala 0 0 0 0 0 0 1
41 b/o shobana 0 1 1 0 0 1 0
42 b/o noorul ni 1 0 0 1 0 0 1
43 b/o sivakami 1 0 0 0 0 0 1
44 b/o pooja 0 0 1 0 0 0 0
45 b/opriya 1 0 0 1 0 1 1
46 b/oraji 0 0 0 0 0 0 0
47 b/o sangathamil 1 0 0 0 0 0 0
48 b/osumathi 1 0 1 0 0 0 0
49 b/o chitra 0 0 1 0 0 1 0
50 b/o kanimoz 1 0 0 0 0 1 1
51 b/o annapoo 1 0 0 0 0 1 0
52 b/oshanthi 0 0 0 1 0 1 1
53 b/ojameela 0 0 0 0 0 0 1
54 b/o ponnuran 1 0 0 0 1 0 0
55 b/o balasund 1 0 0 0 0 0 1
56 b/o sindhu 1 1 1 0 0 0 0
57 b/o punitha 1 0 0 0 0 0 0
58 b/oragava preet 1 0 1 0 0 0 1
59 b/o jeyam 1 0 0 0 0 0 1
60 b/o seethala 0 1 0 0 0 1 1
61 b/okayalvizh 0 0 0 0 0 0 0
62 b/opunitha 1 0 0 0 0 0 0
63 b/okala 0 0 0 0 0 0 1
64 b/oparvathi 1 0 1 0 0 1 0
65 b/opraveena 1 1 1 0 1 1 0
66 b/o suba 1 0 1 0 1 0 0
67 b/olakshmi 1 0 0 0 0 0 0
68 b/opavithra 1 0 1 0 0 1 0
69 b/o deivanai 0 1 0 0 0 0 1
70 b/o kannagav 1 0 0 0 0 0 1
71 b/osaritha 0 0 0 1 0 1 1
72 b/o lalitha 0 0 1 0 0 0 1
73 b/o jeniffer 1 1 1 0 0 0 0
74 b/o lakshana 1 0 1 0 0 0 0
75 b/o nisha 1 0 0 0 1 0 1
76 b/opadma 1 0 0 1 0 1 0
77 b/o delphin 0 0 0 0 0 0 0
78 b/o subathra 1 0 0 0 0 0 0
79 b/o kayal 1 1 0 0 0 0 0
80 b/osurya 0 0 0 0 0 0 1
81 b/o sangeetha 0 0 0 0 0 0 0
82 b/o priyanka 1 0 0 0 0 0 0
83 b/o kanimoz 1 0 0 0 0 0 1
84 b/o rizwana 0 0 0 0 0 0 0
85 b/o sujatha 1 0 1 0 0 0 0
86 b/o nishanthi 0 0 1 0 0 0 0
87 b/o lakshmi 1 1 0 0 1 0 0
88 b/o narmadh 0 0 0 0 0 0 1
89 b/o kanimoz 1 0 0 0 0 0 1
90 b/o subathri 1 0 1 0 1 1 0
91 b/o rani 1 0 0 0 1 0 1
92 b/o stella 1 0 0 1 0 1 0
93 b/o sumithra 1 0 1 0 0 0 0
94 b/o kaviya 1 0 1 0 0 0 0
95 b/o kalairani 0 0 0 0 0 0 1
96 b/o sangeetha 1 0 0 0 0 0 0
97 b/o kundavai 1 0 0 0 0 0 0
98 b/o kalpana 1 0 1 0 1 0 1
99 b/o rajeshwari 1 0 1 0 0 0 1
100 b/o narmadh 1 0 1 0 0 0 0
101 b/o sinnapon 0 1 0 1 0 1 1
102 b/o lingeshwari 0 0 0 0 0 0 0
103 b/o nandhin 1 0 1 0 0 0 0
104 b/o suguna 0 0 0 0 0 0 0
105 b/o lilly 1 0 0 0 0 0 1
106 b/o karpagam 0 0 1 0 0 0 0
107 b/o yasmin 1 1 0 0 0 0 0
108 b/o thenmoz 1 0 1 0 0 0 1
109 b/orejina 0 0 0 0 0 0 0
110 b/o kala 1 0 0 0 0 0 0
Apgar RequiremenTSH value ( mvenous tsh
ROC cut 
off 
>13.1Eme
rgency 
LSCS
ROC cut 
off >15.1 
Resuscitat
ion
ROC cut 
off >13.1 
APGAR
0 0 10.46 0 0 0
0 0 12.03 0 0 0
0 0 9.97 0 0 0
0 0 11.9 0 0 0
0 1 26.4 11.4 1 1 1
0 0 7.08 0 0 0
0 0 7.59 0 0 0
0 0 21.7 10.5 1 1 1
0 0 7.17 0 0 0
0 0 12 0 0 0
1 1 17.5 11 1 1 1
0 0 8.6 0 0 0
0 0 4.98 0 0 0
1 1 20.7 9.6 1 1 1
0 0 6.4 0 0 0
0 0 23.7 8.8 1 1 1
0 0 12.3 0 0 0
0 0 10.5 0 0 0
0 0 6.8 0 0 0
0 0 5.9 0 0 0
0 0 7.52 0 0 0
0 0 20.6 11.7 1 1 1
0 0 13.1 0 0 0
0 0 4.9 0 0 0
0 0 18.5 11.2 1 1 1
0 0 7.5 0 0 0
0 0 22.1 14.8 1 1 1
0 0 14.2 9 1 0 1
1 1 26.3 12.1 1 1 1
0 0 4.48 0 0 0
0 0 7.81 0 0 0
0 0 12.3 0 0 0
0 0 9.82 0 0 0
0 0 6.54 0 0 0
0 0 22.65 10.9 1 1 1
0 0 11.33 0 0 0
0 0 5.6 0 0 0
0 0 8.4 0 0 0
0 0 15.1 8 1 0 1
0 0 7.3 0 0 0
0 0 7.71 0 0 0
0 0 4.33 0 0 0
0 0 9.1 0 0 0
1 1 24.1 9.8 1 1 1
0 0 13.1 0 0 0
0 0 4.5 0 0 0
0 0 8.39 0 0 0
0 0 7.67 0 0 0
0 0 11.5 0 0 0
0 0 13.1 0 0 0
0 0 15.1 8 1 0 1
0 0 11.6 0 0 0
0 0 5.69 0 0 0
0 0 15.6 8.5 1 1 1
1 1 7.71 0 0 0
0 0 6.843 0 0 0
0 0 6.1 0 0 0
0 0 4.32 0 0 0
0 0 13.1 0 0 0
0 0 11.79 0 0 0
0 0 4.8 0 0 0
1 1 15.2 8 1 1 1
0 0 11.1 0 0 0
0 0 6.5 0 0 0
0 0 9.8 0 0 0
0 0 13.6 8 1 0 1
0 0 8.63 0 0 0
0 0 7.52 0 0 0
0 0 6.62 0 0 0
0 0 4.66 0 0 0
0 0 7.51 0 0 0
0 0 8.32 0 0 0
0 0 4.81 0 0 0
0 0 7.83 0 0 0
0 0 8.81 0 0 0
0 0 4.67 0 0 0
0 0 11.23 0 0 0
0 0 5.42 0 0 0
0 0 9.96 0 0 0
1 0 21.8 12.4 1 1 1
0 0 8.42 0 0 0
0 0 4.65 0 0 0
0 0 7.54 0 0 0
0 0 6.22 0 0 0
0 0 7.13 0 0 0
1 0 7.43 0 0 0
0 0 16.5 9.5 1 1 1
0 0 5.33 0 0 0
0 0 9.34 0 0 0
0 0 23.6 13.33 1 1 1
1 0 13.5 8.5 1 0 1
0 0 6.33 0 0 0
0 0 8.71 0 0 0
0 0 6.33 0 0 0
0 0 7.25 0 0 0
0 0 8.43 0 0 0
0 0 10.13 0 0 0
0 0 24.8 10.9 1 1 1
0 0 4.55 0 0 0
1 1 2.78 0 0 0
0 0 7.46 0 0 0
0 0 6.57 0 0 0
0 0 4.49 0 0 0
0 0 9.52 0 0 0
0 0 5.12 0 0 0
0 0 5.88 0 0 0
0 0 6.57 0 0 0
0 0 5.8 0 0 0
0 0 6.1 0 0 0
0 0 7.08 0 0 0
